Defense Medical Research and Development Program - Military Infectious Diseases Clinical Trial Award

The Defense Health Program (Defense Medical Research and Development) has assigned funds to support clinical trials focused on combat-related infectious diseases. This Program Announcement/Funding Opportunity, DMRDP Military Infectious Diseases Clinical Trial Award (MID-CTA), is soliciting proposals focused on wound infection prevention and management as well as antimicrobial countermeasures. The FY12 MID-CTA seeks applications focused on reduction of morbidity and mortality of wound infections in wounded warriors and specifically seeks to accelerate transition of (1) medical technologies into deployed products and (2) advances in knowledge to improve clinical practices for use in the theater of war or in the clinical facilities of the Military Health System (MHS).

Proposed projects should be designed to demonstrate (1) the utility of a novel biomarker/assay, and/or (2) the safety and efficacy of novel therapies in human patients suffering from serious, debilitating wound infections due to trauma. The purpose of such demonstrations is to accelerate translation of greater medical capabilities to patients; this can range from proof of concept (i.e., first in human) trials through Phase II clinical trials, as well as Class I, II, or III medical device trials/testing.

Projects of interest are those focused on testing and translating investigational interventions/devices already proven in relevant definitive animal models, moving them into advanced clinical development.

Please see the link for more details
https://cdmrp.org/files/2012/dmrdp/midcta_pa.pdf

This grant opportunity is worth a maximum of 2,500,000 USD over 3 years


The application deadline is 7 September 2011.